Background: This study was designed to investigate the effect of clopidogrel-related gene polymorphisms on platelet reactivity and clinical outcome in Chinese Han patients. Materials and Methods: Three hundred and thirty-six percutaneous coronary intervention - treated patients were recruited and followed for 1 year. Blood samples were collected from all patients for DNA genotyping. The platelet reactivity unit was measured by the VerifyNow technique. The CYP2C19*2, CYP2C19*3, CYP2C19*17, ATP-binding cassette subfamily B member 1, ITGB3, CYP2C9*3, CYP2B6*9, and P2Y12 alleles were assessed.Results: The clinical endpoints were related to previous heart disease history (11.90% vs.28.57%, P=0.017), stroke (12.24% vs.16.67%, P=0.039), and diabetes (27.55% vs.52.38%, P=0.047). High on-treatment platelet reactivity (HTPR) was frequent in advanced age (P=0.019), male gender (P=0.016), hypertension (P=0.033), and chronic renal failure (P=0.040). There were more endpoints in the CYP2C19*2 and P2Y12 mutant carriers (76.19% vs.43.20%, P<0.001; 50.00% vs.35.71%, P=0.001, respectively), whereas fewer in the CYP2C19*17 mutant carriers (11.90% vs.56.46%, P=0.001). CYP2C19*2 and P2Y12 polymorphism manifested HTPR (194.25 ± 45.91 vs.151.38 ± 58.14, P<0.001; 180.33 ± 67.25 vs.161.89 ± 56.49, P=0.008, respectively), whereas CYP2C19*17 mutant improved platelet reactivity (97.17 ± 45.38 vs.169.08 ± 57.15, P=0.003). However, there were no further cardiovascular deaths in endpoint patients.Conclusion: In Han Chinese people of mainland China, clopidogrel-related gene polymorphisms are related to variable platelet reactivity after clopidogrel maintenance dosing, which influences major adverse cardiovascular events, without an effect on cardiac death.